Cargando…

The concept of treatment-free remission in chronic myeloid leukemia

The advent of tyrosine kinase inhibitors (TKI) into the management of patients with chronic myeloid leukemia (CML) has profoundly improved prognosis. Survival of responders is approaching that of the general population but lifelong treatment is still recommended. In several trials, TKI treatment has...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saußele, S, Richter, J, Hochhaus, A, Mahon, F-X
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4980559/ https://www.ncbi.nlm.nih.gov/pubmed/27133824 http://dx.doi.org/10.1038/leu.2016.115

Ejemplares similares

What is treatment free remission in chronic myeloid leukemia?
por: Rea, Delphine, et al.
Publicado: (2017)

Deep molecular responses for treatment‐free remission in chronic myeloid leukemia
por: Dulucq, Stéphanie, et al.
Publicado: (2016)

Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study
por: Hochhaus, A, et al.
Publicado: (2017)

Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial
por: Radich, Jerald P., et al.
Publicado: (2021)

Treatment-Free Remission—A New Aim in the Treatment of Chronic Myeloid Leukemia
por: Kwaśnik, Paulina, et al.
Publicado: (2021)

Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study
por: Ross, David M., et al.
Publicado: (2018)

Treatment free remission in chronic myeloid leukemia: Lights and shadows
por: Molica, Matteo, et al.
Publicado: (2020)

Onset of blast crisis in chronic myeloid leukemia patients in treatment-free remission
por: Dulucq, Stephanie, et al.
Publicado: (2022)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?
por: Saifullah, Hilbeen Hisham, et al.
Publicado: (2021)

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission
por: Hughes, Amy, et al.
Publicado: (2017)

Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review
por: Rinaldi, Ikhwan, et al.
Publicado: (2023)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
por: Han, Jae Joon
Publicado: (2023)

Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells
por: Chen, Yilin, et al.
Publicado: (2021)

Prospects for achieving treatment‐free remission in chronic myeloid leukaemia
por: Saglio, Giuseppe, et al.
Publicado: (2020)

Leukemia Stem Cells as a Potential Target to Achieve Therapy-Free Remission in Chronic Myeloid Leukemia
por: Ito, Kyoko, et al.
Publicado: (2021)

Survival with chronic myeloid leukaemia after failing milestones
por: Lauseker, Michael, et al.
Publicado: (2023)

Treatment-free remission in chronic myeloid leukemia: the patient perspective and areas of unmet needs
por: Sharf, Giora, et al.
Publicado: (2020)

Telomere length shortening is associated with treatment-free remission in chronic myeloid leukemia patients
por: Caocci, Giovanni, et al.
Publicado: (2016)

Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey
por: Lou, Jin, et al.
Publicado: (2018)

Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia
por: Fujioka, Yuki, et al.
Publicado: (2021)

Treatment-free remission in patients with chronic myeloid leukemia: recommendations of the LALNET expert panel
por: Pavlovsky, Carolina, et al.
Publicado: (2021)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV
por: Saussele, Susanne, et al.
Publicado: (2018)

Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study
por: Yoshida, Chikashi, et al.
Publicado: (2023)

Treatment-Free Remission in Chronic Myeloid Leukemia Harboring Atypical BCR-ABL1 Transcripts
por: Dragani, Matteo, et al.
Publicado: (2020)

Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid Leukemia
por: Breccia, Massimo, et al.
Publicado: (2021)

DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
por: Malighetti, Federica, et al.
Publicado: (2023)

Killer immunoglobulin‐like receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment‐free remission
por: Dumas, Pierre‐Yves, et al.
Publicado: (2019)

Budget Impact of Treatment-Free Remission in Treating Chronic-Phase Philadelphia-Positive Chronic Myeloid Leukemia in Lebanon
por: Elias, Fadia, et al.
Publicado: (2019)

Combination Therapies in Chronic Myeloid Leukemia for Potential Treatment-Free Remission: Focus on Leukemia Stem Cells and Immune Modulation
por: Mu, Hui, et al.
Publicado: (2021)

Budget impact analysis of treatment‐free remission in nilotinib‐treated Japanese chronic myeloid leukemia patients
por: Yamazaki, Kiyotaka, et al.
Publicado: (2020)

Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission
por: Vigón, Lorena, et al.
Publicado: (2020)

P680: PONATINIB 15 MG AS CONSOLIDATION PRIOR TO TREATMENT FREE REMISSION IN CHRONIC MYELOID LEUKEMIA
por: Garcia Gutierrez, Valentin, et al.
Publicado: (2023)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Current Strategies and Future Directions to Achieve Deep Molecular Response and Treatment-Free Remission in Chronic Myeloid Leukemia
por: Annunziata, Mario, et al.
Publicado: (2020)

Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools
por: Castagnetti, Fausto, et al.
Publicado: (2021)

ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia
por: Schönfeld, Lioba, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tn8dus6ain827fev5iljchasdp